In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status
- Additional Document Info
- View All
SOURCE CITATION: Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation. 2021;143:310-21. 33095032.
has subject area